Drug Combination Details
| General Information of the Combination (ID: C85982) | |||||
|---|---|---|---|---|---|
| Name | Resveratrol NP Info | + | Cetuximab Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Lip/oral cavity/pharynx neoplasm
[ICD-11: 2B6E]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Phosphorylation | ERK1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | PLAUR | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | SAS | CVCL_1675 | Tongue squamous cell carcinoma | Homo sapiens | ||
| Sa3 | CVCL_8063 | Gingival squamous cell carcinoma | Homo sapiens | |||
| HSC-3 | CVCL_1288 | Tongue squamous cell carcinoma | Homo sapiens | |||
| In-vivo Model | SAS-R or Sa3-R cells (1*106) were injected subcutaneously into the backs of the female athymic nude mice. | |||||
| Experimental
Result(s) |
Resveratrol targets Urokinase-type plasminogen activator receptor expression to overcome cetuximab-resistance in oral squamous cell carcinoma. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Resveratrol Targets Urokinase-Type Plasminogen Activator Receptor Expression to Overcome Cetuximab-Resistance in Oral Squamous Cell Carcinoma. Sci Rep. 2019 Aug 21;9(1):12179. | |||
